These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27503404)

  • 1. Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes.
    Liu J; Hu Y; Zhang H; Xu Y; Wang G
    J Diabetes Complications; 2016; 30(8):1555-1559. PubMed ID: 27503404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
    Shao N; Kuang HY; Hao M; Gao XY; Lin WJ; Zou W
    Diabetes Metab Res Rev; 2014 Sep; 30(6):521-9. PubMed ID: 24823873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating serum irisin levels in obesity and type 2 diabetes mellitus.
    Shoukry A; Shalaby SM; El-Arabi Bdeer S; Mahmoud AA; Mousa MM; Khalifa A
    IUBMB Life; 2016 Jul; 68(7):544-56. PubMed ID: 27220658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.
    Hu Y; Liu J; Zhang H; Xu Y; Hong T; Wang G
    Diabetes Metab; 2016 Nov; 42(5):358-363. PubMed ID: 27178737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum irisin levels in new-onset type 2 diabetes.
    Choi YK; Kim MK; Bae KH; Seo HA; Jeong JY; Lee WK; Kim JG; Lee IK; Park KG
    Diabetes Res Clin Pract; 2013 Apr; 100(1):96-101. PubMed ID: 23369227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesity.
    Komosinska-Vassev K; Gala O; Olczyk K; Jura-Półtorak A; Olczyk P
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32917052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
    Iglesias P; Civantos S; Vega B; Pavón I; Guijarro G; Monereo S
    Obes Surg; 2015 Mar; 25(3):575-8. PubMed ID: 25589020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
    Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: A cross sectional and a prospective case-control study nested in the Normative Aging Study.
    Sahin-Efe A; Upadhyay J; Ko BJ; Dincer F; Park KH; Migdal A; Vokonas P; Mantzoros C
    Metabolism; 2018 Feb; 79():24-32. PubMed ID: 29108900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irisin in the Glucose Continuum.
    Assyov Y; Gateva A; Tsakova A; Kamenov Z
    Exp Clin Endocrinol Diabetes; 2016 Jan; 124(1):22-7. PubMed ID: 26479549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.
    Dutour A; Abdesselam I; Ancel P; Kober F; Mrad G; Darmon P; Ronsin O; Pradel V; Lesavre N; Martin JC; Jacquier A; Lefur Y; Bernard M; Gaborit B
    Diabetes Obes Metab; 2016 Sep; 18(9):882-91. PubMed ID: 27106272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower circulating irisin is associated with type 2 diabetes mellitus.
    Liu JJ; Wong MD; Toy WC; Tan CS; Liu S; Ng XW; Tavintharan S; Sum CF; Lim SC
    J Diabetes Complications; 2013; 27(4):365-9. PubMed ID: 23619195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
    Nguyen H; Dufour R; Caldwell-Tarr A
    Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of Irisin Hormone Level in Type 2 Diabetic Patients and Patients with Diabetic Nephropathy.
    Shelbaya S; Abu Shady MM; Nasr MS; Bekhet MM; Mageed YA; Abbas M
    Curr Diabetes Rev; 2018; 14(5):481-486. PubMed ID: 28875825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients].
    Wang XH; Han LN; Yu YR; Wang C; Wang B; Wen XR; Huang H; Jing XC
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 46(4):586-90. PubMed ID: 26480664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.
    Topyildiz F; Kiyici S; Gul Z; Sigirli D; Guclu M; Kisakol G; Cavun S
    J Diabetes Res; 2016; 2016():1309502. PubMed ID: 26998491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of psoriasis during exenatide treatment in a patient with diabetes.
    Buysschaert M; Tennstedt D; Preumont V
    Diabetes Metab; 2012 Feb; 38(1):86-8. PubMed ID: 22227407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.